The CR + PR rate of triweekly therapy group is 30.3 % MST is 41.2 weeks one-year survival rate is 33.3 % .

3 周方案组有效率（CR+PR）30.3%，中位生存时间41.2周，1年生存率33.3%。

Objective To contrast the effect and the adverse effects of Docetaxel plus Cisplatin semimonthly therapy with that of triweekly therapy in advanced nonsmall-cell lung cancer ( NSCLC ) .

目的对比研究紫杉醇联合顺铂双周方案与 三 周 方案治疗晚期非小细胞肺癌的疗效及不良反应。